NCT05057182 is a Phase 4 clinical trial of BNT162b2 in COVID 19 Vaccine, sponsored by The University of Hong Kong.

Who is sponsoring NCT05057182?

NCT05057182 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT05057182?

Interventions in NCT05057182: BNT162b2.

What condition does NCT05057182 study?

NCT05057182 studies COVID 19 Vaccine.

Is NCT05057182 still recruiting?

NCT05057182 is currently status unknown. Last updated 11 December 2023.

Last reviewed 2023-12-11 · How we verify

NCT05057182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)

Status unknown Phase 4 Last updated 11 December 2023

What this trial tests

Phase 4 trial testing BNT162b2 in COVID 19 Vaccine in 300 participants. Status unknown.

Timeline

18 October 2021

Primary endpoint
31 March 2024

31 December 2024

Quick facts

Lead sponsor	The University of Hong Kong
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	300
Start date	18 October 2021
Primary completion	31 March 2024
Estimated completion	31 December 2024
Sites	1 location across Hong Kong

Drugs / interventions tested

BNT162b2 (bnt162b2) — full drug profile →

Conditions studied

COVID 19 Vaccine — all drugs for COVID 19 Vaccine →

Sponsor

The University of Hong Kong

Who can join

30 and older, any sex, with COVID 19 Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech). Investigators will monitor reactogenicity and measure the immune response to the third dose.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, et al · · 2022 · cited 368× · PMID 35322018 · DOI 10.1038/s41392-022-00950-y
COVID-19 vaccine development: milestones, lessons and prospects.
Li M, Wang H, Tian L, Pang Z, et al · · 2022 · cited 298× · PMID 35504917 · DOI 10.1038/s41392-022-00996-y
Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.
Huang Y, Guo X, Wu Y, Chen X, et al · · 2024 · cited 188× · PMID 38378653 · DOI 10.1038/s41392-024-01745-z
Nanoparticles in clinical trials of COVID-19: An update.
Rauf A, Abu-Izneid T, Khalil AA, Hafeez N, et al · · 2022 · cited 22× · PMID 35953020 · DOI 10.1016/j.ijsu.2022.106818
Key Design Features of Lipid Nanoparticles and Electrostatic Charge-Based Lipid Nanoparticle Targeting.
Gyanani V, Goswami R. · · 2023 · cited 20× · PMID 37111668 · DOI 10.3390/pharmaceutics15041184
Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.
Leung NHL, Cheng SMS, Martín-Sánchez M, Au NYM, et al · · 2023 · cited 19× · PMID 35675370 · DOI 10.1093/cid/ciac458
COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review.
Simnani FZ, Singh D, Kaur R. · · 2022 · cited 18× · PMID 34926119 · DOI 10.1007/s13205-021-03076-0
Lipid Nanoparticle-Based Delivery System-A Competing Place for mRNA Vaccines.
Zhang X, Li Y, Zhou Z. · · 2024 · cited 15× · PMID 38371811 · DOI 10.1021/acsomega.3c08353

Verify or expand the search:

Other trials of BNT162b2

Trials testing the same drug.

NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05621239 — A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People · completed
NCT05343871 — Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase · Phase 4 · completed
NCT05310084 — Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age · Phase 3 · completed
NCT05289037 — COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) · Phase 2 · completed

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05057182 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 11 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing